Skip to main
TNYA
TNYA logo

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc. has demonstrated promising early clinical data, with protein levels in Patient 1 showing a significant increase of over 50% from Week 8 to Week 52, indicating positive biological activity of its TN-401 gene therapy candidate. The recent receipt of an $8 million CLIN2 grant from the California Institute of Regenerative Medicine (CIRM) further strengthens the company's financial position and enhances its ability to fund ongoing clinical research. Additionally, the company's strategic focus on rapid advancement through clinical development and potential expansion into other indications positions Tenaya for significant upside potential in the future.

Bears say

Tenaya Therapeutics Inc faces significant risks that could adversely affect its financial outlook, particularly related to potential delays in transitioning its preclinical assets to clinical trials and the emergence of safety signals during those trials. The complexities associated with manufacturing AAV-based gene therapy products could further constrain the company’s development and commercialization efforts, impacting forecasts and market sentiment. Additionally, if the company fails to secure adequate funding or experiences setbacks in clinical trials, it may face downward revisions to its financial estimates and valuation.

Tenaya Therapeutic (TNYA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Buy based on their latest research and market trends.

According to 6 analysts, Tenaya Therapeutic (TNYA) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.